NAVIDEA BIOPHARMACEUTICALS, INC. (NYSEAMERICAN: NAVB) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

NAVIDEA BIOPHARMACEUTICALS, INC. (NYSEAMERICAN: NAVB) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item 5.02.Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

Story continues below

On November 21, 2018, the Company appointed Kathy Rouan, Ph.D., as a director. Dr.Rouan’s appointment, which will be effective on December 1, 2018, was made to the class with terms expiring at the annual meeting of stockholders to be held in 2019. Dr. Rouan was not appointed to serve on any committees of the Board, although she may be appointed to one or more committees at a later date. On November 26, 2018, the Company issued a press release relating to the appointment of Dr. Rouan, which is filed as Exhibit 99.1 to this report and is incorporated herein by reference.

Similar to other non-employee directors, Dr. Rouan will receive compensation for her service as director in accordance with the Company’s non-employee director compensation program.

There is no arrangement or understanding between Dr. Rouan and any other person to which she was selected as a director of the Company and there are no family relationships between Dr. Rouan and any of the Company’s directors or executive officers. There are no transactions to which the Company is a party and in which Dr. Rouan has a direct or indirect material interest that would be required to be disclosed under Item 404(a) of Regulation S-K.

In connection with her appointment, Dr. Rouan is expected to enter into a standard Director Agreement with the Company, a form of which was previously filed by the Company with the U.S. Securities and Exchange Commission on May 10, 2016, and which is incorporated by reference herein.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.


NAVIDEA BIOPHARMACEUTICALS, INC. Exhibit
EX-99.1 2 ex_130827.htm EXHIBIT 99.1 ex_130827.htm Exhibit 99.1   Navidea Biopharmaceuticals Appoints Dr. Kathy Rouan to Board of Directors   DUBLIN,…
To view the full exhibit click here

An ad to help with our costs